Activity of the Antiseptic Polyhexanide Against Gram-Negative Bacteria

The activity of the antiseptic polyhexanide was tested against 250 gram-negative clinical isolates, that is, 50 isolates each of Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Moraxella catarrhalis , and Haemophilus influenzae . Minimal inhibitory concentrations (MICs) and minim...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Microbial drug resistance (Larchmont, N.Y.) N.Y.), 2014-04, Vol.20 (2), p.138-143
Hauptverfasser: Fabry, Werner Hugo Karl, Kock, Hans-Jürgen, Vahlensieck, Winfried
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 143
container_issue 2
container_start_page 138
container_title Microbial drug resistance (Larchmont, N.Y.)
container_volume 20
creator Fabry, Werner Hugo Karl
Kock, Hans-Jürgen
Vahlensieck, Winfried
description The activity of the antiseptic polyhexanide was tested against 250 gram-negative clinical isolates, that is, 50 isolates each of Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Moraxella catarrhalis , and Haemophilus influenzae . Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) were determined by using a serial broth microdilution technique according to DIN 58940. Time-kill studies were performed for reference stains E. coli ATCC 25922, K. pneumoniae ATCC 4352, P. aeruginosa ATCC 15442, M. catarrhalis ATCC 43617, and H. influenzae ATCC 49247. All tested isolates had MICs and MBCs within a range of 1–32 mg/L and were regarded as susceptible to polyhexanide. The highest values were found for P. aeruginosa and H. influenzae with MICs and MBCs of 32 mg/L. Addition of up to 4% albumin to the test medium did not change MICs and MBCs. Time-kill studies of the reference strains showed reduction rates from 3 log 10 colony forming units (CFU)/ml to more than 5 log 10 CFU/ml for 200 and 400 mg/L polyhexanide within 5–30 min. Testing of polyhexanide in combination with antibiotics showed indifference with amoxicillin, cefotaxime, imipenem, gentamicin, and ciprofloxacin; no antagonism was found. As no resistance and no antagonism with antibiotics were detected, polyhexanide is regarded as suitable agent for topical eradication of gram-negative bacteria.
doi_str_mv 10.1089/mdr.2013.0113
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1516739427</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1516739427</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-4e581827f5877007266d7beec0c79a06a756f6e51b004f7fc449963d3431f9ec3</originalsourceid><addsrcrecordid>eNqN0T1PwzAQBmALgWgpjKwoEgtLyjl27HgsFV9SBQwwR65zAVf5KLaL6L_HVQsDC0y2Ts-ddPcSckphTKFQl23lxhlQNgZK2R4ZUsVoWnBe7Mc_SJGKTPEBOfJ-AQA5FeyQDDJOVcaUHJKbiQn2w4Z10tdJeMNk0gXrcRmsSZ76Zv2Gn7qzVay_atv5kNw63aYP-KpjGyZX2gR0Vh-Tg1o3Hk9274i83Fw_T-_S2ePt_XQySw1TRUg55gUtMlnnhZQAMhOiknNEA0YqDULLXNQCczoH4LWsDedKCVYxzmit0LARudjOXbr-fYU-lK31BptGd9ivfEnjgpIpnsn_UADFuMgiPf9FF_3KdXGRqEDFMzJRRJVulXG99w7rculsq926pFBusihjFuUmi3KTRfRnu6mreYvVj_4-fgRsCzZl3XWNxTm68MfYL0Hdky8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1509107368</pqid></control><display><type>article</type><title>Activity of the Antiseptic Polyhexanide Against Gram-Negative Bacteria</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Fabry, Werner Hugo Karl ; Kock, Hans-Jürgen ; Vahlensieck, Winfried</creator><creatorcontrib>Fabry, Werner Hugo Karl ; Kock, Hans-Jürgen ; Vahlensieck, Winfried</creatorcontrib><description>The activity of the antiseptic polyhexanide was tested against 250 gram-negative clinical isolates, that is, 50 isolates each of Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Moraxella catarrhalis , and Haemophilus influenzae . Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) were determined by using a serial broth microdilution technique according to DIN 58940. Time-kill studies were performed for reference stains E. coli ATCC 25922, K. pneumoniae ATCC 4352, P. aeruginosa ATCC 15442, M. catarrhalis ATCC 43617, and H. influenzae ATCC 49247. All tested isolates had MICs and MBCs within a range of 1–32 mg/L and were regarded as susceptible to polyhexanide. The highest values were found for P. aeruginosa and H. influenzae with MICs and MBCs of 32 mg/L. Addition of up to 4% albumin to the test medium did not change MICs and MBCs. Time-kill studies of the reference strains showed reduction rates from 3 log 10 colony forming units (CFU)/ml to more than 5 log 10 CFU/ml for 200 and 400 mg/L polyhexanide within 5–30 min. Testing of polyhexanide in combination with antibiotics showed indifference with amoxicillin, cefotaxime, imipenem, gentamicin, and ciprofloxacin; no antagonism was found. As no resistance and no antagonism with antibiotics were detected, polyhexanide is regarded as suitable agent for topical eradication of gram-negative bacteria.</description><identifier>ISSN: 1076-6294</identifier><identifier>EISSN: 1931-8448</identifier><identifier>DOI: 10.1089/mdr.2013.0113</identifier><identifier>PMID: 24192397</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Anti-Bacterial Agents - pharmacology ; Anti-Infective Agents, Local - pharmacology ; Antibiotics ; Bacteria ; Bacterial infections ; beta-Lactams - pharmacology ; Biguanides - pharmacology ; Ciprofloxacin - pharmacology ; Drug Combinations ; Drug resistance ; E coli ; Epidemiology ; Escherichia coli ; Escherichia coli - drug effects ; Escherichia coli - growth &amp; development ; Gentamicins - pharmacology ; Gram-negative bacteria ; Haemophilus influenzae ; Haemophilus influenzae - drug effects ; Haemophilus influenzae - growth &amp; development ; Klebsiella pneumoniae ; Klebsiella pneumoniae - drug effects ; Klebsiella pneumoniae - growth &amp; development ; Microbial Sensitivity Tests ; Microbial Viability - drug effects ; Microbiology ; Moraxella (Branhamella) catarrhalis - drug effects ; Moraxella (Branhamella) catarrhalis - growth &amp; development ; Moraxella catarrhalis ; Pseudomonas aeruginosa ; Pseudomonas aeruginosa - drug effects ; Pseudomonas aeruginosa - growth &amp; development</subject><ispartof>Microbial drug resistance (Larchmont, N.Y.), 2014-04, Vol.20 (2), p.138-143</ispartof><rights>2014, Mary Ann Liebert, Inc.</rights><rights>(©) Copyright 2014, Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-4e581827f5877007266d7beec0c79a06a756f6e51b004f7fc449963d3431f9ec3</citedby><cites>FETCH-LOGICAL-c398t-4e581827f5877007266d7beec0c79a06a756f6e51b004f7fc449963d3431f9ec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24192397$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fabry, Werner Hugo Karl</creatorcontrib><creatorcontrib>Kock, Hans-Jürgen</creatorcontrib><creatorcontrib>Vahlensieck, Winfried</creatorcontrib><title>Activity of the Antiseptic Polyhexanide Against Gram-Negative Bacteria</title><title>Microbial drug resistance (Larchmont, N.Y.)</title><addtitle>Microb Drug Resist</addtitle><description>The activity of the antiseptic polyhexanide was tested against 250 gram-negative clinical isolates, that is, 50 isolates each of Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Moraxella catarrhalis , and Haemophilus influenzae . Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) were determined by using a serial broth microdilution technique according to DIN 58940. Time-kill studies were performed for reference stains E. coli ATCC 25922, K. pneumoniae ATCC 4352, P. aeruginosa ATCC 15442, M. catarrhalis ATCC 43617, and H. influenzae ATCC 49247. All tested isolates had MICs and MBCs within a range of 1–32 mg/L and were regarded as susceptible to polyhexanide. The highest values were found for P. aeruginosa and H. influenzae with MICs and MBCs of 32 mg/L. Addition of up to 4% albumin to the test medium did not change MICs and MBCs. Time-kill studies of the reference strains showed reduction rates from 3 log 10 colony forming units (CFU)/ml to more than 5 log 10 CFU/ml for 200 and 400 mg/L polyhexanide within 5–30 min. Testing of polyhexanide in combination with antibiotics showed indifference with amoxicillin, cefotaxime, imipenem, gentamicin, and ciprofloxacin; no antagonism was found. As no resistance and no antagonism with antibiotics were detected, polyhexanide is regarded as suitable agent for topical eradication of gram-negative bacteria.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Infective Agents, Local - pharmacology</subject><subject>Antibiotics</subject><subject>Bacteria</subject><subject>Bacterial infections</subject><subject>beta-Lactams - pharmacology</subject><subject>Biguanides - pharmacology</subject><subject>Ciprofloxacin - pharmacology</subject><subject>Drug Combinations</subject><subject>Drug resistance</subject><subject>E coli</subject><subject>Epidemiology</subject><subject>Escherichia coli</subject><subject>Escherichia coli - drug effects</subject><subject>Escherichia coli - growth &amp; development</subject><subject>Gentamicins - pharmacology</subject><subject>Gram-negative bacteria</subject><subject>Haemophilus influenzae</subject><subject>Haemophilus influenzae - drug effects</subject><subject>Haemophilus influenzae - growth &amp; development</subject><subject>Klebsiella pneumoniae</subject><subject>Klebsiella pneumoniae - drug effects</subject><subject>Klebsiella pneumoniae - growth &amp; development</subject><subject>Microbial Sensitivity Tests</subject><subject>Microbial Viability - drug effects</subject><subject>Microbiology</subject><subject>Moraxella (Branhamella) catarrhalis - drug effects</subject><subject>Moraxella (Branhamella) catarrhalis - growth &amp; development</subject><subject>Moraxella catarrhalis</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Pseudomonas aeruginosa - growth &amp; development</subject><issn>1076-6294</issn><issn>1931-8448</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqN0T1PwzAQBmALgWgpjKwoEgtLyjl27HgsFV9SBQwwR65zAVf5KLaL6L_HVQsDC0y2Ts-ddPcSckphTKFQl23lxhlQNgZK2R4ZUsVoWnBe7Mc_SJGKTPEBOfJ-AQA5FeyQDDJOVcaUHJKbiQn2w4Z10tdJeMNk0gXrcRmsSZ76Zv2Gn7qzVay_atv5kNw63aYP-KpjGyZX2gR0Vh-Tg1o3Hk9274i83Fw_T-_S2ePt_XQySw1TRUg55gUtMlnnhZQAMhOiknNEA0YqDULLXNQCczoH4LWsDedKCVYxzmit0LARudjOXbr-fYU-lK31BptGd9ivfEnjgpIpnsn_UADFuMgiPf9FF_3KdXGRqEDFMzJRRJVulXG99w7rculsq926pFBusihjFuUmi3KTRfRnu6mreYvVj_4-fgRsCzZl3XWNxTm68MfYL0Hdky8</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Fabry, Werner Hugo Karl</creator><creator>Kock, Hans-Jürgen</creator><creator>Vahlensieck, Winfried</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20140401</creationdate><title>Activity of the Antiseptic Polyhexanide Against Gram-Negative Bacteria</title><author>Fabry, Werner Hugo Karl ; Kock, Hans-Jürgen ; Vahlensieck, Winfried</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-4e581827f5877007266d7beec0c79a06a756f6e51b004f7fc449963d3431f9ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Infective Agents, Local - pharmacology</topic><topic>Antibiotics</topic><topic>Bacteria</topic><topic>Bacterial infections</topic><topic>beta-Lactams - pharmacology</topic><topic>Biguanides - pharmacology</topic><topic>Ciprofloxacin - pharmacology</topic><topic>Drug Combinations</topic><topic>Drug resistance</topic><topic>E coli</topic><topic>Epidemiology</topic><topic>Escherichia coli</topic><topic>Escherichia coli - drug effects</topic><topic>Escherichia coli - growth &amp; development</topic><topic>Gentamicins - pharmacology</topic><topic>Gram-negative bacteria</topic><topic>Haemophilus influenzae</topic><topic>Haemophilus influenzae - drug effects</topic><topic>Haemophilus influenzae - growth &amp; development</topic><topic>Klebsiella pneumoniae</topic><topic>Klebsiella pneumoniae - drug effects</topic><topic>Klebsiella pneumoniae - growth &amp; development</topic><topic>Microbial Sensitivity Tests</topic><topic>Microbial Viability - drug effects</topic><topic>Microbiology</topic><topic>Moraxella (Branhamella) catarrhalis - drug effects</topic><topic>Moraxella (Branhamella) catarrhalis - growth &amp; development</topic><topic>Moraxella catarrhalis</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Pseudomonas aeruginosa - growth &amp; development</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fabry, Werner Hugo Karl</creatorcontrib><creatorcontrib>Kock, Hans-Jürgen</creatorcontrib><creatorcontrib>Vahlensieck, Winfried</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Microbial drug resistance (Larchmont, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fabry, Werner Hugo Karl</au><au>Kock, Hans-Jürgen</au><au>Vahlensieck, Winfried</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activity of the Antiseptic Polyhexanide Against Gram-Negative Bacteria</atitle><jtitle>Microbial drug resistance (Larchmont, N.Y.)</jtitle><addtitle>Microb Drug Resist</addtitle><date>2014-04-01</date><risdate>2014</risdate><volume>20</volume><issue>2</issue><spage>138</spage><epage>143</epage><pages>138-143</pages><issn>1076-6294</issn><eissn>1931-8448</eissn><abstract>The activity of the antiseptic polyhexanide was tested against 250 gram-negative clinical isolates, that is, 50 isolates each of Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Moraxella catarrhalis , and Haemophilus influenzae . Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) were determined by using a serial broth microdilution technique according to DIN 58940. Time-kill studies were performed for reference stains E. coli ATCC 25922, K. pneumoniae ATCC 4352, P. aeruginosa ATCC 15442, M. catarrhalis ATCC 43617, and H. influenzae ATCC 49247. All tested isolates had MICs and MBCs within a range of 1–32 mg/L and were regarded as susceptible to polyhexanide. The highest values were found for P. aeruginosa and H. influenzae with MICs and MBCs of 32 mg/L. Addition of up to 4% albumin to the test medium did not change MICs and MBCs. Time-kill studies of the reference strains showed reduction rates from 3 log 10 colony forming units (CFU)/ml to more than 5 log 10 CFU/ml for 200 and 400 mg/L polyhexanide within 5–30 min. Testing of polyhexanide in combination with antibiotics showed indifference with amoxicillin, cefotaxime, imipenem, gentamicin, and ciprofloxacin; no antagonism was found. As no resistance and no antagonism with antibiotics were detected, polyhexanide is regarded as suitable agent for topical eradication of gram-negative bacteria.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>24192397</pmid><doi>10.1089/mdr.2013.0113</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1076-6294
ispartof Microbial drug resistance (Larchmont, N.Y.), 2014-04, Vol.20 (2), p.138-143
issn 1076-6294
1931-8448
language eng
recordid cdi_proquest_miscellaneous_1516739427
source MEDLINE; Alma/SFX Local Collection
subjects Anti-Bacterial Agents - pharmacology
Anti-Infective Agents, Local - pharmacology
Antibiotics
Bacteria
Bacterial infections
beta-Lactams - pharmacology
Biguanides - pharmacology
Ciprofloxacin - pharmacology
Drug Combinations
Drug resistance
E coli
Epidemiology
Escherichia coli
Escherichia coli - drug effects
Escherichia coli - growth & development
Gentamicins - pharmacology
Gram-negative bacteria
Haemophilus influenzae
Haemophilus influenzae - drug effects
Haemophilus influenzae - growth & development
Klebsiella pneumoniae
Klebsiella pneumoniae - drug effects
Klebsiella pneumoniae - growth & development
Microbial Sensitivity Tests
Microbial Viability - drug effects
Microbiology
Moraxella (Branhamella) catarrhalis - drug effects
Moraxella (Branhamella) catarrhalis - growth & development
Moraxella catarrhalis
Pseudomonas aeruginosa
Pseudomonas aeruginosa - drug effects
Pseudomonas aeruginosa - growth & development
title Activity of the Antiseptic Polyhexanide Against Gram-Negative Bacteria
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T10%3A43%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activity%20of%20the%20Antiseptic%20Polyhexanide%20Against%20Gram-Negative%20Bacteria&rft.jtitle=Microbial%20drug%20resistance%20(Larchmont,%20N.Y.)&rft.au=Fabry,%20Werner%20Hugo%20Karl&rft.date=2014-04-01&rft.volume=20&rft.issue=2&rft.spage=138&rft.epage=143&rft.pages=138-143&rft.issn=1076-6294&rft.eissn=1931-8448&rft_id=info:doi/10.1089/mdr.2013.0113&rft_dat=%3Cproquest_cross%3E1516739427%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1509107368&rft_id=info:pmid/24192397&rfr_iscdi=true